Expert Rev Mol Diagn 2002 Nov;2(6):627-33
Ohta M, Ohta K.
Department of Clinical Chemistry, Kobe Pharmaceutical University, Higashinadu-ku, Kobe 658-8558, Japan.
Radioimmunoassay for myelin basic protein in cerebrospinal fluid is commonly used as a biochemical marker of demyelination in multiple sclerosis patients.
A sensitive enzyme-linked immunosorbent assay for myelin basic protein has been recently developed, which can make a clinical evaluation of myelin basic protein in cerebrospinal fluid of patients with multiple sclerosis and other neurological diseases.
Most multiple sclerosis patients with acute exacerbation had markedly high myelin basic protein.
Longitudinal studies of multiple sclerosis patients showed tha tmyelin basic protein in CSF increases rapidly in agreement with acute relapse and then rapidly declines and disappears.
Significantly higher cerebrospinal fluid myelin basic protein levels in human T-cell lymphotropic virus Type I-associated myelopathy/tropical spastic paraparesis patients were also detected.
This enzyme-linked immunosorbent assay system can be used routinely to measure myelin basic protein in cerebrospinal fluid as a useful diagnostic indicator, not only for central active demyelination as in multiple sclerosis but, also for spinal cord demyelination as in human T-cell lymphotropic virus Type I-associated myelopathy/tropical spastic paraparesis.